The Application Value of Spectral CT in the Accurate Staging of Liver Cancer
ConditionLiver Cancer
Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-80
SponsorYunnan Cancer Hospital
About this trial
Spectral CT was used to prospectively collect medical images and clinical data related to liver cancer, evaluate the effect of image quality in the diagnosis of liver cancer, and evaluate the application value in the accurate staging of liver cancer, so as to provide a more accurate clinical basis for diagnosis, promote the development of individualized treatment, and ultimately improve the prognosis of patients.
Eligibility criteria
Qualifiers
Undergo a contrast-enhanced Quark Spectral CT scan of the lower abdomen/pelvis within 1 week before treatment.
Age > 18 years.
Patients suspected of having liver cancer.
Patients who have signed the informed consent form.
Disqualifiers
Severe cardiac, pulmonary, or renal insufficiency.
Allergy to iodine-based contrast agents.
Inability to cooperate with the CT examination.
Poor image quality of the Quark Spectral CT scan.
Trial design
Treatments tested in this trial
- To explore the value of spectral CT in the diagnosis and treatment of liver cancer
Treatment groups
150 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov